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Abstract
Connective tissue growth factor (CTGF) is an important mediator of fibrosis; emerging evidence link changes in plasma and
urinary CTGF levels to diabetic kidney disease. To further ascertain the role of CTGF in responses to high glucose, we
assessed the consequence of 4 months of streptozotocin-induced diabetes in wild type (+/+) and CTGF heterozygous (+/2)
mice. Subsequently, we studied the influence of glucose on gene expression and protein in mice embryonic fibroblasts
(MEF) cells derived from wildtype and heterozygous mice. At study initiation, plasma glucose, creatinine, triglyceride and
cholesterol levels were similar between non-diabetic CTGF+/+ and CTGF+/2 mice. In the diabetic state, plasma glucose
levels were increased in CTGF+/+ and CTGF+/2 mice (28.2 3.3 mmol/L vs 27.0 3.1 mmol/L), plasma triglyceride levels were
lower in CTGF+/2 mice than in CTGF+/+ (0.7 0.2 mmol/L vs 0.5 0.1 mmol/L, p,0.05), but cholesterol was essentially
unchanged in both groups. Plasma creatinine was higher in diabetic CTGF+/+ group (11.761.2 vs 7.960.6 mmol/L p,0.01),
while urinary albumin excretion and mesangial expansion were reduced in diabetic CTGF+/2 animals. Cortices from
diabetic mice (both CTGF +/+ and CTGF +/2) manifested higher expression of CTGF and thrombospondin 1 (TSP1).
Expression of nephrin was reduced in CTGF +/+ animals; this reduction was attenuated in CTGF+/2 group. In cultured MEF
from CTGF+/+ mice, glucose (25 mM) increased expression of pro-collagens 1, IV and XVIII as well as fibronectin and
thrombospondin 1 (TSP1). In contrast, activation of these genes by high glucose was attenuated in CTGF+/2 MEF. We
conclude that induction of Ctgf mediates expression of extracellular matrix proteins in diabetic kidney. Thus, genetic
variability in CTGF expression directly modulates the severity of diabetic nephropathy.
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Introduction
CTGF (CCN2) is a pleiotropic growth factor belonging to the
30–40 kDa CCN family of proteins which includes Cyr61, NOV
and WISP1. This family of proteins exhibits a diverse array of
cellular effects (mitogenesis, apoptosis, regulation of extracellular
matrix (ECM) physiology, osteogenesis, embryogenesis, angiogen-
esis and tumorigenesis), are critical for growth, development and
differentiation and are responsive to various intra- and extracel-
lular stimuli (please see references [1–4] for detailed review).
CTGF, product of the gene Ctgf, is considered as an important
mediator of fibrosis [4,5], yet many of the signals involved in this
process remain unknown.
High glucose induces Ctgf expression in human vascular smooth
muscle cells (VSMC) and this is accompanied by increased
expression of fibronectin and collagen type 1 [6]. In non-primate
human models with diabetes, glomerular and tubular ctgf
expression correlated with albuminuria and glomerular basement
thickness [7]. In addition to the reported positive association
between Ctgf expression and extracellular matrix proteins, recent
data derived from a Col1a2 promoter insertional transgenic mice
model directly link increased Ctgf overexpression with fibrosis in
multiple organs including kidney [8]. It is also worth noting that,
whereas a polymorphism in ctgf promoter has been linked with
systemic sclerosis [9–11] and infectious hepatic fibrosis [12], these
observations have not been consistent [13–15].
There is emerging evidence that link changes in plasma and
urinary CTGF levels to diabetic nephropathy. Plasma CTGF
levels are elevated in persons with type 1 DM and plasma CTGF
levels have been correlated with proteinuria and creatinine
clearance [16]. Likewise, in a study of persons with type 1 DM,
urinary CTGF levels were elevated in those with diabetic
nephropathy and correlated with albumin excretion rate (AER)
and glomerular filtration rate (GFR) [17]. In addition, an
evaluation of glomerular CTGF protein in biopsies from type 1
diabetic patients revealed increased CTGF expression as disease
progressed from incipient to advanced nephropathy [18]. In STZ-
induced diabetic and ob/ob diabetic mice, glomerular Ctgf
expression also mirrored development of nephropathy and
correlated with urinary CTGF protein [19]. These observations
strongly suggest a pathologic role for CTGF in diabetic
nephropathy and, as well, a recent report [20] provides putative
mechanistic insights into the manner in CTGF may affect matrix
biology in the setting of hyperglycemia and/or diabetes mellitus.
The current study examined the effect of systemic Ctgf expression
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Dulbecco’s modified Eagle’s medium (DMEM), penicillin-
Streptomycin and trypsin (0.05%)-EDTA solutions were pur-
chased from Invitrogen (Carlsbad, CA, USA). Restrictions
enzymes were from New England Biolabs (Ipswich, MA, USA),
while Effectene transfection reagent was procured from Qiagen
(Valencia, CA, USA). Except where stated, all other chemicals
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Kits
for determination of plasma triglyceride (product No: 461-08992),
cholesterol (product No: 439-17501) and glucose (product no: 439-
90901) were sourced from Wako Diagnostics (Richmond, VA,
USA). Blood urea nitrogen (BUN; product no: 700620) was
measured with assay kits from Cayman Chemical (Ann Arbor, MI,
USA).
Animals
All animal experiments were carried out after approval from,
and in accordance with, the Institutional Animal Care and Use
Committees at UT Southwestern Medical Center at Dallas
(Animal Protocol Number 0993-06-02-1) and the University of
North Carolina at chapel Hill (Protocol Numbers 07-228 and 05-
046). 129S6 wildtype mice were purchased from Taconic
(Hudson, NY, USA), while C57BL/6 wildtype mice were from
Charles River Laboratories (Wilmington, MA, USA). CTGF
knockout mice were generated through gene targeting in 129S6
mouse embryonic stem (ES) cells by replacing exons 3 to 5 of
endogenous ctgf with a neomycin resistance (neo) cassette (figure 1).
Mice carrying the mutated ctgf gene were subsequently generated
by standard techniques [21] and maintained on a 129S6 inbred
background. Mice were kept on 12-hour light-dark cycle at
ambient temperatures of 68uF to 72uF and had free access to water
and food (regular rodent diet [diet# 2014, Harlan Teklad,
Madison, WI]).
Intraperitoneal (IP) STZ injections
Mice (n = 10/group) were rendered diabetic by employing a low
dose STZ protocol [22]. Briefly, mice were injected with freshly
prepared STZ dissolved in 0.05M citrate buffer (0.05 ml; pH 4.5)
at a dose of 40 mg/g BW on five consecutive days. Control animals
(n = 9) were injected with citrate buffer only. Mice were followed
for up to 4 months following the induction of diabetes.
Physiologic/Metabolic Studies
Mice were placed in metabolic cages (Hatteras Instruments,
Cary NC) overnight with free access to food and water. Body
weight, food intake, water consumption and urine volume were
recorded before and after the study interval. Following induction
of anesthesia with Avertin (2,2,2-tribromoethanol, 1.25%), blood
was obtained from the retro-orbital sinus of each mouse using a
microcapillary tube (0.075 ml; Fisher Scientific). Urine albumin
was determined using commercially available kits (Exocell Inc.
PA). Albumin excretion rate, AER (mg/24 hours) was estimated
from the urine albumin determined by ELISA. Creatinine was
determined by capillary electrophoresis (UT Southwestern
O’Brien Core Lab) using a P/ACE MDQ Capillary Electropho-
resis System (Beckman Coulter Inc) as previously reported [23,24].
Prior to capillary electrophoresis, plasma specimen (0.1 ml) were
treated with trichloroacetic acid (TCA; 5% [v/v]; 0.1 ml) and
precipitate proteins were removed by centrifugation (30006g/
5 minutes) [24].
Histology
Following euthanasia, carcasses were initially perfused (perfu-
sion pressure 70 and 100 mm Hg) with phosphate-buffered saline
(PBS, 10 mls over 1 min via gravity feed)) solution and
subsequently with paraformaldehyde (PFA [4% v/v]; 50 mls over
4 minutes). Fixed kidney sections were dehydrated, embedded in
paraffin, and 3–4 mM sections were made for histologic analyses.
Specimens were analyzed by light microscopy to assess glomerular
and renal tubular histology. Mesangial matrix expansion was
estimated by a semi-quantitative method [25]. Changes observed
on PAS-stained sections were assigned a value of 1 to 4, in a
blinded fashion by 2 observers, depending on the number of
glomeruli manifesting matrix expansion. Accordingly values were
assigned as follows: score 0, a normal glomerulus; score 1,
increased mesangial matrix of up to 25% of glomerular tuft; score
2, mesangial expansion of 25 to 50% of glomerular tuft; sore 3,
mesangial expansion of 50 to 75%; and score 4, mesangial
expansion of .75% of the tuft.
Immunohistochemistry
Paraformaldehyde-fixed paraffin-embedded tissues were cut
into 4-mm sections. The slides were heated (30 minutes, 56uC),
then deparaffinized (three washes; 5 minutes each) in HistoClear
(National Diagnostics, Atlanta, GA, USA) and rehydrated through
a graded alcohol series (100%, 95%, and 70% washes for
5 minutes each wash). For antigen retrieval, the slides were
autoclaved in 10 mM sodium citrate buffer. Sections were pre-
incubated in PBS and then blocked in PBS containing 5% bovine
serum albumin (BSA) and 1% goat serum (30 minutes at room
temperature). The sections were incubated overnight at 4uC with
primary antibodies against insulin (sc-7838;1:100; Santa Cruz
Biotechnologies) and glucagon (sc-13091; 1:100; Santa Cruz
Biotechnologies). The sections were rinsed with PBS and
incubated with IgG secondary antibody conjugated to Alexa
Fluor 488 or Alexa Fluor 555 (Molecular Probes; 1:400) for 1 h at
room temperature, and counterstained with 49-6-diamidino-2-
phenylindole (DAPI, Boehringer Mannheim; 1:5000). Fluorescent
signals were visualized by using a Zeiss Axioplan 2 Imaging
System (Carl Zeiss MicroImaging Inc., Thornwood, NY, USA).
Cell Isolation and Culture
Mouse embryonic fibroblasts (MEF) were prepared from
ED12.5 to ED14.5 embryos [26]. Stable lines of spontaneously
immortalized MEF were generated by serial splitting as described
[27]. Primary mouse mesangial cells (MMC) were prepared from 2
month old male wildtype 129S6 mice by the sieving method
[28,29]. Cells between passage 8 and 12 were used in these studies.
Cells were initially plated on plastic culture dishes and maintained
(37uC/5%CO2) in DMEM/10% fetal bovine serum (FBS)
supplemented with penicillin (100 IU/ml)/Streptomycin
(100 mg/ml). Twenty-four hours later, medium was changed to
one containing 0.5% FBS with and without high glucose (25 mM),
or inhibitors for ERK, p38MAPK and JNK. Cells were cultured
for an additional 48 hours prior to harvesting.
CTGF and Thrombospondin 1 promoter-Luciferase
Reporter Constructs
To generate a mouse thrombospondin 1 (TSP1) gene promoter,
a 1.3 kb Sac1/HindIII fragment encompassing the transcriptional
start site and upstream promoter region was synthesized as above
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using primers 59-ATAGAGCTCCCCTGATTCTGCCAA-
GATCCT-39 and 59-TAAAAGCTTATGAGGCTGGCT-
GACTCCAG-39. Following confirmation of sequence fidelity
(UT Southwestern sequencing Core), the promoter fragment was
ligated into a luciferase reporter vector (pGL3 Basic; Promega
Corporation). The resultant Tsp1-luciferase construct (pTsp-Luc)
was used for transient expression in wild-type primary MMC or in
(MEF) respectively.
Transfection
MMC (1.56105 cells/well) or MEF were plated onto six-well
plastic plates (Falcon #353224, Becton Dickinson, NJ, USA), and
transfection was carried out 24 hours later using Effectene
(QIAGEN) according to the manufacturer’s specifications. Briefly,
cells (70–80% confluent) were co-transfected with 0.25 mg of pTsp-
Luc, and 0.05 mg of pCMVbgal and then cultured for 18 h in
DMEM containing FBS (20%) and 5.6 mmol/l D-glucose. With
the use of CMV promoter-driven green fluorescent protein
construct, the efficiency of transfection was estimates to 35–40%.
Subsequently, the media was changed to DMEM with 0.5% FBS
and glucose (5.6 or 25 mmol/l) and MMC were incubated for an
additional 48 hours prior to harvesting.
ECM protein Expression in MEF
ECM expression was analyzed with a commercially available
expression profiling kit (product #PM-012B, SA Biosciences).
Briefly, cells (16106/100 mm plate) were seeded in DMEM
containing FBS (10%) and D-glucose (5.6 mmol/L) for 24 hours.
Subsequently, the media was changed to DMEM with 0.5% FBS
and glucose (5.6 or 25 mmoles/L) for 48 hours. At the end of this
period, cells were harvested and total RNA was isolated by
standard methods [30]. Gene expression was subsequently
analyzed by RT-PCR per manufacturer’s specifications.
Western Blot Analysis
This was performed as we have previously described [31,32].
Subsequent to retrieval of kidney from euthanized animals
(0.5 mls 2.5% Avertin), protein was extracted from kidney cortical
slices suspended in MPER protein extraction reagent (product
No. 78503, Pierce, Rockford, IL) in the presence of protease
inhibitors (product No. P8340, Sigma-Aldrich) using a homoge-
nizer (Kinematica, Luzen, Switzerland). Protein extracts were
separated using 12% SDS-polyacrylamide gel electrophoresis
under reducing conditions. The separated proteins were trans-
ferred to nitrocellulose membranes and incubated with commer-
cially available rabbit polyclonal (primary) antibodies to either
CTGF (GTX25097, GeneTex, San Antonio, TX), Nephrin (sc-
28192, Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA),
thrombospondin 1 (AB2962; Abcam, Cambridge, MA) or
fibronectin (sc-9068, Santa Cruz Biotechnology Inc, Santa Cruz,
CA, USA). Subsequently, CTGF, thrombospondin 1 and fibro-
nectin were identified with peroxidase conjugated anti-rabbit
secondary antibody, and ECL Western blotting analysis system
Figure 1. Generation of mice with disrupted Ctgf gene. Depiction of wildtype allele is represented in Panel A. I,II, III, IV and V represents exons
1 to 5 of Ctgf gene. The arrow straddling exons I and II represents 59 probe. B (for BamHI); NheI and NciI represent restriction enzyme sites. Targeted
allele (Panel B) demonstrating loss of exons III to V following recombination in ES cells. Neo represents neomycin resistance gene. Southern blot
analysis of genomic DNA is shown in Panel C. The targeted allele was identified by 59probe that hybridizes to a 5 kb fragment in the heterozygous
and 12 kb fragment in the wildtype. PCR of genomic DNA from MEF is represented in Panel D. In panel A, a,b and c indicate location of primers used
for PCR, whereas B denotes restriction site for BamH1. Primers a and b gives a 550 bp endogenous product, while primers a and c gives a 320 bp
targeted product as indicated in panel D.
doi:10.1371/journal.pone.0070441.g001
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(Amersham). Autograms were quantified by scanning densitome-
try.
RT-PCR
Total RNA was extracted from MEF and kidney cortex using
TRIzol reagent (Invitrogen, Carlsbad, CA) in accordance with the
manufacturer’s protocol. Gene expressions were determined using
real-time quantitative reverse transcription PCR (RT-PCR)
(Applied Biosystems, Foster City, California, USA) with b-actin
as the reference gene in each reaction [33].
Statistical Analysis
All statistical analyses were performed using the JMP statistical
Software (SAS Institute, Cary, NC). Values are reported as mean
6 standard deviation. Comparison between groups was assessed
with ANOVA and the Tukey test; differences were considered
significant at p,0.05.
Results
Characteristic of CTGF-Knockout Line
CTGF gene knockout (CTGF2/2) mice were generated by
replacing exons 3 to 5 of Ctgf with bacterial neomycin resistance
(Neo) through gene-targeting in 129 SvEv-Tac derived embryonic
stem (ES) cells as described in the methods (above). Total RNA
from tail snips and mice embryonic fibroblasts [30] was used for
RT-PCR. Quantitative RT-PCR (qRT-PCR) performed using
total RNA from tail and kidney cortex revealed that Ctgf
expression in heterozygous was approximately 50% of the level
in wildtype mice (Figure 2A and B). In kidney specimen from
heterozygous mice, the level of CTGF protein was about 60% of
that in control (wildtype) littermates (Figure 2C).
Homozygous gene-disrupted (CTGF2/2) mice die within
24 hours of birth, but heterozygous offspring survive and thrive
normally. Fertility, growth and development features, relevant
physiologic and hematologic parameters of heterozygous mice
(CTGF+/2) are not significantly different from wildtype (CTGF+/+)
littermates (Table 1). Several of these findings are similar to that
described for Ctgf disruption by other investigators [34]. However,
blood pressure was lower in heterozygous mice compared with
wildtype littermates (table 1).
Proteinuria is attenuated in diabetic ctgf heterozygous
mice
Given the putative role of CTGF in the response to elevated
levels of extracellular glucose and diabetes mellitus, we performed
studies to determine the effect of streptozotocin (STZ)-induced
diabetes mellitus on plasma creatinine and albuminuria in
CTGF+/2 mice. Mice were rendered diabetic with the low dose
STZ protocol [22], while control animals received citrate buffer
(vehicle). Two mice from the STZ group and one from the control
(buffer only) group died over the course of the study. Data from
these animals have not been included in the analysis. Diabetic
CTGF+/+ and CTGF+/2 mice consumed more food and water
and produced more urine than their non-diabetic counterparts
(Figure S1). However, there were no differences between diabetic
mice of both genotype with respect to food and water consumption
or urine output. Likewise, there were no significant differences in
body weight amongst the 4 groups of animals (Figure S1).
Plasma glucose increased after the STZ treatment, but was not
different between the CTGF+/+ and CTGF+/2 mice throughout
the study (table 2). Although CTGF+/+ animals had plasma
glucose levels similar to CTGF+/2 mice (28.263.3 vs
27.063.1 mmol/L), the latter group had lower plasma creatinine
levels (7.960.6 vs 11.761.2 mmoles/L, p,0.01; figure 3A).
Likewise, blood urea nitrogen (BUN) and urinary albumin/
creatinine ratio were significantly attenuated in diabetic CTGF+/2
when compared with their diabetic CTGF+/+ group (figure 3B
and C). Whereas plasma cholesterol was unaffected by diabetes,
plasma triglyceride was significantly lower in diabetic CTGF+/2
mice compared with CTGF+/+ animals (table 2). Histologic and
immunohistochemical analysis of endocrine and exocrine pancreas
from non-diabetic wildtype and heterozygous animals (Figure S2)
did not reveal any obvious basal differences between the groups
that may account for observed variation in glucose or triglyceride
disposal.
CTGF influences Mesangial Matrix accumulation
The data in the previous section suggest that albuminuria is less
severe in diabetic CTGF+/2 mice than in CTGF+/+ animals,
suggesting that reduced Ctgf expression may offer protection
against proteinuric kidney disease in this model. As CTGF is
implicated in ECM production, the effect on kidney size and
Figure 2. CTGF mRNA levels in kidneys from newborn (A) and
1-month old mice (B). Total RNA was isolated and expression was
determined by qRT-PCR as described in methods. Panel C depicts CTGF
protein levels in kidney from wildtype and heterozygous adult mice.
Protein was determined by Western blotting analysis. *p,0.05; n = 6.
doi:10.1371/journal.pone.0070441.g002
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glomerular matrix was assessed. As expected, diabetes lead to
increases in kidney mass in both CTGF+/+ and CTGF+/2
animals, but the difference between the two groups of diabetic
animals was not significant (figure 4A). We observed reduced
mesangial expansion in diabetic CTGF+/2 relative to their
CTGF+/+ littermates (figure 4B to E). The latter finding was
further bolstered by the observation of lower mesangial expansion
scores in diabetic CTGF+/2 when compared with diabetic
CTGF+/+ mice (Figure 4F). Simplification of tubular epithelial
cells was observed in kidney sections from diabetic animals
(Figure 4d). Masson-Trichrome stained sections showed mild
interstitial fibrosis, but this was not markedly different from that
observed in non-diabetic wildtype and heterozygous animals
(Figure S3).
High-glucose induced expression of extracellular matrix
proteins is dependent on CTGF
CTGF has been shown to mediate expression of extracellular
matrix (ECM) proteins in response to various external perturba-
tions [6,35]. To further delineate the role of CTGF role in the
cellular response to high ambient glucose levels, we initially
examined the levels of known extracellular matrix protein by mice
embryonic fibroblasts (MEF). Matrix accumulation in diabetic and
other proteinuric kidney diseases may be mediated by resident
fibroblast and mesangial cells. Some studies suggest that cells with
phenotypes of mesangial cells and fibroblasts (fibroblast/myofi-
broblast) are the cell type most responsible for matrix accumula-
tion that is observed in proteinuric kidney diseases, like diabetes
[36,37]. Fibroblast cell lines were selected for study to reflect
properties of both cell types (mesangial cells and fibroblasts).
Accordingly, MEF were isolated from CTGF+/+ and CTGF+/2
embryos. Stable lines of CTGF+/+ and CTGF+/2 MEFs were
exposed to physiologic or high glucose (25 mmoles/L) for
48 hours and extracted total RNA was used to assess the impact
on extracellular matrix proteins expression using a commercially
available expression panel.
In CTGF+/+ cells, high ambient glucose induces a 2- to 3-fold
increase in expression of several ECM proteins including a1-
collagen 1 (Col1a1), a2-collagen IV (Col IVa2), a1-collagen
XVIII (Col18a1), fibronectin (Fn) and thrombospondin 1 (Tsp-1)
(Figure 5A and table S1). The observation for Col18a1 has not
being previously reported, but the effects of high glucose on the
other ECM protein expression are consistent with earlier reports
for other cell lines [6,35]. In contrast, in CTGF+/2 cells exposed
to high ambient glucose, expression of the aforementioned ECM
proteins was attenuated (figure 5A). The data further support a
role of CTGF in mediating the cellular response to high
extracellular glucose levels that accompanies diabetes mellitus.
Tsp1 is induced in cells cultured under high glucose conditions
[38]. In humans with type 1diabetes, progressive increases in
CTGF and TSP1 accompanies the development and progression
of diabetic kidney disease; in mesangial cells, CTGF mediated




Number of Animals (n) 8 8
Glucose (mmol/L) 6.961.7 7.560.8
Triglyceride (mmol/L) 0.460.2 0.360.1
Cholesterol (mmol/L) 3.460.4 3.160.5
Creatinine (mmol/L) 5.861.2 6.061.1
BUN (mmol/L) 12.161.0 11.562.8
Hematocrit (%) 4961.5 50.561.1
PT (seconds) 12.160.2 11.960.
Blood Pressure (Systolic, mmHg) 11264 *10163




Figure 3. Plasma creatinine (A), urea nitrogen (BUN, [B]) and urinary
albumin to creatinine ratio (C) are increased in diabetic wildtype (+/+)
and CTGF heterozygous (+/2) mice after 4 months of STZ-induced
diabetes mellitus. For all parameters, the increase for CTGF heterozy-
gous animals was significantly less when compared to that for wildtype
littermates. Values represent the mean 6 standard deviation; *p,0.01;
#p,0.05; NS – not significant; n = 8.
doi:10.1371/journal.pone.0070441.g003
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glucose-induced fibronectin synthesis [18]. However the effect of
CTGF on TSP1 is ill-defined. Given the observation that Tsp1
expression was attenuated in Ctgf heterozygous MEF, we chose to
corroborate the finding of the expression array by initially studying
activation of TSP1 promoter-luciferase reporter and secondly by
assessing TSP1 protein levels in cells cultured under physiologic
and high glucose conditions. As indicated in figure 5 B, CTGF+/+
MEF exposed to high glucose show an increase in TSP1 promoter
activity suggesting transcriptional regulation. In CTGF+/2 and
CTGF2/2 MEFs, there was attenuation of Tsp1 promoter activity
further supporting a role for CTGF in Tsp1 promoter activity.
Similarly, TSP1 protein levels were increased by high glucose in
CTGF+/+ MEFs and attenuated in CTGF+/2 and CTGF2/2
MEFs (figure 5 C). However, for TSP1 protein and promoter
activity, the difference between CTGF+/2 and CTGF2/2 MEFs
was not significant. In line with the observations in MEFs, we
observed that both CTGF and TSP1 messages were increased in
kidney cortex from diabetic CTGF+/+ compared with kidney
derived from diabetic CTGF+/2 mice (figure 6). In contrast,
nephrin expression was decreased in diabetic CTGF+/+ mice but
unchanged in diabetic CTGF+/2 mice (figure 6).
Discussion
A significant consequence of abnormal response to injury is
increased expression of CTGF. CTGF mediates induction of genes
for various extracellular proteins including thrombospondin I
(TSP1) in bleomycin induced pulmonary fibrosis, plasminogen
activator inhibitor type 1 (PAI-1) and collagen I, III and IV in rat
kidney fibroblasts [39–41]. In addition, there is emerging evidence
that link changes in plasma and urinary CTGF levels to diabetic
nephropathy [16–19]. Recent observations suggest that ctgf
overexpression is sufficient to mediate fibrosis [8]. Accordingly,
we sought to determine the effect of systemic ctgf expression on
kidney function, albuminuria and susceptibility to diabetic kidney
disease in an animal model with diminished Ctgf.
The initial observation, that homozygous gene-disrupted mice
die within 24 hours of birth, is similar to that published by other
investigators in which mice on a mixed C57Bl/6 – 129S6
background were studied [34]. This implies that the early post-
natal demise, that we and other have observed, reflects an
important role for CTGF in perinatal survival which is indepen-
dent of background strain of the mice. On the other hand, several
parameters (blood pressure, lipids, creatinine, BUN) which have
been determined for CTGF+/2 mice in the current study (Table 1)
have not been previously reported. In the current study,
parameters that have been previously reported are not different
from those of CTGF+/+ littermates, suggesting that ctgf heterozy-
gosity did not appear to exert significant influence in the non-
diabetic state.
Systemic blood pressure was lower in heterozygous compared
with wildtype mice. However, the reason(s) for this difference in
blood pressure between wild type mice and those that are
heterozygous for ctgf are unclear and have not been previously
reported. Likewise, the impact of CTGF on system blood pressure
is unknown. RAAS blockade, that classically lead to better blood
pressure control, improvement in proteinuria and renal protection,
has been associated with reduced CTGF expression [42,43].
However, this effect is related to upstream influence of RAAS on
CTGF, rather than inherent effect of CTGF. Nonetheless, given
that CTGF can influence extracellular matrix protein like collagen
and fibronectin, it is conceivable that this may in turn affect blood
vessel, peripheral resistance and systemic blood pressure.
We observed that in STZ-diabetic mice, Ctgf heterozygosity
attenuates increases in plasma creatinine levels, albumin excretion
and mesangial matrix expansion. Using a related mouse model
[34], ctgf heterozygosity has also been found to be protective with
respect to albuminuria and proteinuria in animals with diabetes
[20]. These observations, that a roughly 50% reduction in the Ctgf
expression attenuates changes in kidney function, provide a
possible causative link between progressive kidney disease (man-
ifested by albuminuria and/or urinary albumin/creatinine ratio)
and Ctgf expression. Plasma creatinine was not reported in the
study by Nguyen et al [20], probably because of the difficulty of
measuring this parameter in mice plasma. In the current study,
utilizing capillary electrophoresis, we have found that in STZ
diabetic mice changes in plasma creatinine occur in concert with
albuminuria and that ctgf heterozygosity mitigates these changes.
In line with these latter findings, we also observed attenuation of
mesangial expansion in the diabetic CTGF+/2 mice compared
with diabetic CTGF+/+ animals. Attenuation of mesangial
expansion in CTGF+/2 mice is consistent with observations
highlighted by another report [20] and further supports a role for
CTGF in the production of ECM proteins in response to high
extracellular glucose. Simplification of tubular epithelial cells was
observed in kidney sections from diabetic animals (Figure 4d).
Masson-Trichrome stained sections showed mild interstitial
fibrosis, but this was not markedly different from that observed
in non-diabetic wildtype and heterozygous animals (Figure 3).
These observations are in accord with that reported for genetic
diabetic models studied from age 8–10 weeks for 4 months [44].
Hypertriglyceridemia is a feature of diabetes mellitus [45]. In
the current study, plasma triglyceride levels were similar in
wildtype and heterozygous animals (table 1). However, in the
diabetic state there was a modest, but significant increase in
plasma triglyceride in wildtype compared to heterozygous mice
(table 2). The reason(s) for difference between the two groups of
animals in the diabetic state is not known. Plasma triglyceride
levels are determined by production and clearance of TG
containing lipoproteins [46]. Pancreatic lipase participates in
clearance of triglyceride carried in lipoprotein moieties (primarily
chylomicrons and very low density lipoproteins) [47,48], but the
impact of CTGF on lipase production, release or activity is
unknown. CTGF may be important in pancreatic islet develop-
ment [49] and may have an influence on pancreatic cancer
development [50]. However, histology examination (H&E and
IHC studies; Figure 2) did not reveal differences between the two
groups. Nonetheless, because of a putative role for CTGF in




Number of Animals (n) 8 8
Glucose (mmol/L) 28.263.3 27.063.1 NS
Triglyceride (mmol/L) 0.760.2 0.560.1 ,0.05
Cholesterol (mmol/L) 3.660.4 3.960.6 NS
Creatinine (mmol/L) 11.761.2 7.960.6 ,0.01
BUN (mmol/L) 18.661.9 1461.8 ,0.01
Hematocrit (%) 4862.5 51.363.1 NS
Blood Pressure (mmHg) 109614 10468 NS
Note: Values represent mean 6 SD; NS – not significant.
doi:10.1371/journal.pone.0070441.t002
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pancreatic development, it is possible that CTGF may, through
effects on exocrine and endocrine pancreas, impact triglyceride-
rich lipoprotein metabolism.
Overall, difference between the current study and that
previously reported [20] may be due to genetic background.
Indeed, genetic background has a significant impact on diabetic
phenotype in mice [44,51]. In particular 129 mice manifest greater
Figure 4. Kidney/body weight ratios are increased in diabetic mice, without a significant difference between diabetic wildtype and
heterozygous mice (Panel A). Representative kidney sections from non-diabetic wildtype [B] and CTGF heterozygous [C] and diabetic wildtype
mouse [D] and diabetic CTGF heterozygous littermates [E] reveal increase in mesangial matrix is attenuated in diabetic CTGF heterozygous mice as
compared to that observed in kidneys from wildtype animals. Panel F depicts estimated mesangial expansion score for the various groups. Kidneys
were perfusion-fixed with PFA (4%), embedded in paraffin and sectioned (4 mm) followed by PAS staining. Original magnification 6200; *p,0.01;
#p,0.05.
doi:10.1371/journal.pone.0070441.g004
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degree of proteinuria and mesangial matrix expansion compared
with C57BL/6. Thus, our observation that the phenotype
described in this study was more robust than that reported by
Nguyen et. al. [20] likely reflects strain differences. We used 129
line while a mixed C57BL/6-129 was used by Nguyen et. al.
To further study the role of CTGF in ECM response to high
extracellular glucose, we examined the effect of Ctgf expression on
ECM from cells cultured in high glucose. Stable MEFs were
generated from embryos (see ‘Methods’) and expression of ECM
proteins was determined following exposure to physiologic or high
glucose levels. Amongst the genes studied, col1a1, col4a2,
Col18a1 and fibronectin 1 (Fn1) and thrombospondin 1 (TSP1)
were all increased in CTGF+/+ cells. In this series of experiments
we observed that reduced ctgf expression attenuated expression of
several ECM proteins (figure 5A and Table S1). Col18a1
expression in diabetic kidney disease has not been previously
reported. However, the findings with respect to col4a2, Col18a1
and TSP1 are significant because of their potential role in fibrosis
and anti-angiogenesis. Procollagen IV and procollagen XVIII are
parent molecules of anti-angiogenic factors tumstatin and endo-
statin respectively, while TSP1 has potent anti-angiogenic and
pro-fibrotic properties [52,53]. The observation that collagen
XVIII is upregulated by hyperglycemia was unexpected. Collagen
XVIII has been identified in basement membrane of vascular and
epithelial cells [54]. In this regard, collagen XVIII may be
protective in immune-mediated glomerulonephritis in that colla-
gen XVIII deficient mice develop more severe glomerular disease
than wildtype littermate [55]. Collagen XVIII may also affect
podocytes in that variable foot process effacement has been
described in collagen XVIII knockout mice [56]. On the other
hand, a role for collagen XVIII in the pathogenesis of diabetic
kidney disease remains unclear. Although reduction in ctgf
expression may not protect again fibrosis that occurs in severe
injury [57], overall our observations implicate ctgf expression as a
mediator of ECM protein expression in response to high-glucose.
TSP1 is induced in cells cultured under high glucose conditions
[38] and CTGF may influence TSP1 levels in cultured renal
interstitial fibroblasts [58]. In this context, some studies suggest
that TSP1 is key regular is transforming growth factor beta
(TGFb) activity and that glucose-induced TGFb bioactivity is
mediated by TSP1 [59]. In humans with type 1 diabetes mellitus,
progressive increases in CTGF and TSP1 accompany the
development and progression of diabetic kidney disease and, in
mesangial cells, CTGF mediates glucose-induced fibronectin
synthesis [18]. In line with these earlier observations, we found
that CTGF+/+ MEF exposed to high glucose (25 mM) manifested
a significant increase in expression of ECM proteins including
TSP1 (figure 5, panel A). The observation for TSP1 was confirmed
with TSP1 promoter-luciferase reporter system (figure 5, panel C)
and western blotting analysis (figure 5, panel B). Our observation
of increased TSP1 expression in kidney (figure 6) supports these in
vitro observations. The associated observation that ctgf expression
was attenuated in kidney derived from CTGF+/2 mice (figure 6) is
in line with previously published data [20]. Likewise, in diabetes, a
reduction in nephrin expression and commitment increase in Ctgf
expression have been previously reported [60]. Our current
observations support these recent findings.
Reduced Ctgf expression in heterozygous cells attenuated high
glucose-induced TSP-1 expression. However, in ctgf-null MEFs,
the effect of high glucose on TSP1 expression was not abolished
(figure 5) suggesting that other pathways participate in this
response to high glucose. Nonetheless, the findings indicate that
TSP1 expression is influenced by high glucose at the level of
transcription and are consistent with observation reported by other
investigators [38]. Overall, our observation that CTGF increases
expression of ECM proteins, like collagens and TSP-1, support an
important role for CTGF in ECM expression and bears important
implications for tissue fibrosis as a consequence of hyperglycemia.
The role of CTGF in pathogenesis of a complex trait, like
diabetic kidney disease, is unresolved. CTGF gene polymorphism
has been linked to susceptibility to kidney disease in type 1 diabetes
Figure 5. ECM expression of selected genes in wildtype (+/+)
and heterozygous (+/2) MEF cell lines exposed to high glucose
(25 mM) for 48 hours (A). The changes have been normalized to
that observed in physiologic glucose (5.6 mM). TSP1 promoter
expression (B) and protein (C) are increased by high glucose in wild
type MEF and attenuated in ctgf-heterozygous and knockout MEFs.
ECM expression array studies were done in duplicate and repeated
twice. All other experiments were performed in triplicates and repeated
at least 3 times. Values are mean +/2 SD. *p,0.05; #P,0.01.
Abbreviations: wildtype +/+; heterozygous +/2; knockout 2/2; Col1a1
– alpha 1 collagen type I; Col4a2- alpha 2 collagen type IV; Fn1 –
fibronectin 1; Col18a1 – alpha 1 collagen type XVIII; TSP1 –
thrombospondin 1.
doi:10.1371/journal.pone.0070441.g005
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mellitus [61] and may also be a prognostic risk factor for
cardiovascular outcomes in hemodialysis patients [62]. Yet, other
report show no link between at least one polymorphism (-945G/C)
in CTGF gene and kidney disease in types 1 and 2 diabetes
[63,64]. The findings of the current study further support a role for
ctgf expression in the pathogenesis of diabetic kidney disease. In
addition, we show that ctgf expression is an important mediator of
ECM protein expression in response to high glucose. Future
studies will be needed to further delineate the role of CTGF and
signaling pathways in this response.
Supporting Information
Figure S1 Food consumption (A), water intake (B), urine output
(C) and body weight (D) in diabetic and non-diabetic wildtype (+/
+) and heterozygous (+/2) mice after 4 months of STZ-induced
diabetes mellitus. Values represent the mean 6 standard
deviation; *p,0.01; n = 8.
(TIF)
Figure S2 Masson-Trichrome stained sections of pancreas from
Ctgf wildtype (A) and heterozygous (B) mice. Immunohistochem-
ical studies from wildtype (C) and heterozygous (D) identifying
insulin-staining beta cells (yellow-red) and glucagon-staining alpha
cells (green) in pancreatic islets. Exocrine pancreas (red) and DAPI
stained nuclei (blue) are also shown in panels C and D;
Magnification 6400.
(JPG)
Figure S3 Representative Masson-Trichrome-stained kidney
sections from non-diabetic wildtype (+/+) [A] and CTGF
heterozygous (+/2) [B] and diabetic wildtype [C] and CTGF
heterozygous littermates [D] reveal tubular simplification with
diabetes, without significant interstitial fibrosis.
(JPG)
Table S1 Changes in expression of ECM-related genes
in embryonic fibroblasts (MEF) derived from wild-type
and knockout embryos following exposure to high
glucose. Expression was determined using an expression profiling
kit (product #PM-012B, SA Biosciences). mRNA levels are
expressed as mean 6 SD relative to mRNA levels for
glyceraldehye-3-phosphate dehydrogenase. NS – not significant.
(DOCX)
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